FOVEA PHARMACEUTICALS
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.
FOVEA PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2005-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.fovea-pharma.com
Total Employee:
1+
Status:
Closed
Total Funding:
107.01 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Nginx SAKURA Internet
Similar Organizations
Tibotec
Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV .
Current Advisors List
Current Employees Featured
Founder
Investors List
Abingworth
Abingworth investment in Series B - Fovea Pharmaceuticals
Wellcome Trust
Wellcome Trust investment in Series B - Fovea Pharmaceuticals
Sofinnova Partners
Sofinnova Partners investment in Series B - Fovea Pharmaceuticals
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Fovea Pharmaceuticals
Gimv
Gimv investment in Series B - Fovea Pharmaceuticals
Credit Agricole CIB
Credit Agricole CIB investment in Series B - Fovea Pharmaceuticals
Sofinnova Partners
Sofinnova Partners investment in Series A - Fovea Pharmaceuticals
Gimv
Gimv investment in Series A - Fovea Pharmaceuticals
Credit Agricole CIB
Credit Agricole CIB investment in Series A - Fovea Pharmaceuticals
Official Site Inspections
http://www.fovea-pharma.com
- Host name: lb-182-253.above.com
- IP address: 103.224.182.253
- Location: Australia
- Latitude: -33.494
- Longitude: 143.2104
- Timezone: Australia/Sydney
More informations about "Fovea Pharmaceuticals"
Fovea Pharmaceuticals - Crunchbase Company Profile & Funding
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the …See details»
Fovea Pharmaceuticals - Company Profile - Tracxn
Oct 31, 2024 Fovea Pharmaceuticals ranks 69th among 201 active competitors. 69 of its competitors are funded while 57 have exited. Overall, Fovea Pharmaceuticals and its …See details»
Fovea Pharmaceuticals - Overview, News & Similar companies
Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the tr eatment of ocular diseases, with a …See details»
Fovea Pharmaceuticals - PitchBook
Fovea Pharmaceuticals General Information Description. Developer of drugs for the treatment of ocular diseases. The company provides drugs for the treatment of diseases such as retinal …See details»
Fovea Pharmaceuticals SA - Paris, France - bionity.com
Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the …See details»
Fovea Pharmaceuticals to be Acquired by Sanofi-Aventis
Oct 1, 2009 For more information, please visit www.fovea-pharma.com . Fovea Pharmaceuticals SA: Bernard Davitian Chief Financial Officer +33 1 44 16 42 61 [email protected] …See details»
MPS partners with Sanofi to develop innovative solutions for …
Max Planck Society (Max-Planck-Gesellschaft), Germany’s leading basic research organization, announced today that it has signed with Fovea Pharmaceuticals, the Ophthalmology Division …See details»
Fovea Pharmaceuticals SAS - Company Profile and News
Company profile page for Fovea Pharmaceuticals SAS including stock price, company news, executives, board members, and contact informationSee details»
Emerging Drug Developer: Fovea Pharmaceuticals - Fierce Biotech
Fovea eyes big markets for retinal diseases Before Bernard Gilly, Ph.D., made a career switch and jumped into venture capital, he was the CEO of Transgene. But while he was a partner at …See details»
Sanofi-Aventis To Acquire Fovea - Pharmaceutical Business review
Fovea’s three products in clinical development are – FOV 1101, an eye drop, fixed dose combination of prednisolone and cyclosporine, currently in phase II for the treatment of …See details»
FOVEA PHARMA Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for FOVEA PHARMA of Madurai, Tamil Nadu. Get the latest business insights from Dun & Bradstreet.See details»
Sanofi-Aventis Buying Fovea Pharma for €370 Million
Oct 1, 2009 Sanofi-Aventis has agreed to acquire Fovea Pharmaceuticals SA, a Paris, France-based drug company focused on ophthalmic diseases. The deal is valued at up to €370 …See details»
Sanofi-aventis fait l’acquisition de FOVEA, une biotech française ...
Oct 1, 2009 Sanofi-aventis poursuit sa stratégie d’acquisitions et annonce aujourd’hui la signature d’un accord en vue de l’acquisition de Fovea, une société privée biopharmaceutique …See details»
Gimv portfolio company Fovea to be acquired by Sanofi-aventis
Oct 1, 2009 Gimv portfolio company Fovea to be acquired by Sanofi-aventis. Portfolio. Life Sciences. 01/10/2009 - 17:45 ...See details»
Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Oct 1, 2009 Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular …See details»
Sanofi-Aventis Inks $539M Deal to Purchase Fovea
Oct 1, 2009 Money includes an up-front payment and milestones for Fovea’s three clinical compounds related to eye diseases. Sanofi-Aventis is purchasing Fovea Pharmaceuticals for …See details»
Fovea Pharmaceuticals Completes $25 million Series A ... - BioSpace
PARIS, November 7 /PRNewswire/ -- Fovea Pharmaceuticals SA (Fovea), a biopharmaceutical company created in May 2005 by a team of experienced scientists and managers, announced …See details»
Fovea Pharmaceuticals to be acquired by sanofi-aventis - Reliable …
Fovea Pharmaceuticals announced October 1 that it has entered into a binding agreement with sanofi-aventis to sell 100 percent of its share to sanofi-aventis. Fovea has a portfolio of three …See details»
Fovea Pharmaceuticals Enter Into a Research Collaboration in
Nov 27, 2007 Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of …See details»
Home - Braintale - Braintale
Then she moved to the biotech world, joining Fovea Pharma in 2009, that became Ophthalmology Division of Sanofi. She contributed to the start of Tissium (2014 – Head of Development), …See details»